Subanalysis of the OZIRKA study: efficacy of Ozalex (rosuvastatin) in patients with diabetes mellitus

Authors

  • Yu.M. Sirenko State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine, Ukraine
  • O.O. Torbas State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine, Ukraine
  • S.M. Kushnir State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine, Ukraine

DOI:

https://doi.org/10.22141/2224-1485.14.2.2021.231854

Keywords:

diabetes mellitus, arterial hypertension, dyslipidemia, rosuvastatin

Abstract

Background. Diabetes mellitus (DM) remains one of the most important cardiovascular risk factors significantly worsening the prognosis in patients with hypertension and dyslipidemia. The leading role among drugs for the treatment of such patients belongs to statins with their powerful influence on the development and progression of atherosclerosis and its complications. We used the OZIRKA study database and performed additional subanalysis to study the effects of rosuvastatin in patients with diabetes and dyslipidemia. Purpose: to study the effect of Ozalex (rosuvastatin) on lipid and cholesterol levels in patients with lipid metabolism disorders and hypercholesterolemia and DM. Materials and methods. It was a prospective open population study. The recruitment of patients was conducted from March to December 2019. The analysis of the study data was conducted from June to November 2020. Results. A total of 20,000 patients from all over Ukraine were included in the study. The full follow-up period was completed by 18,100 patients, of whom 17,530 had all the necessary data, they were included in the final analysis. The mean follow-up period was 2.2 months. Approximately 13 % of patients included in the study had DM type 2. We observed a significant reduction in total cholesterol, low-density lipoprotein (LDL) and triglyceride levels in patients with diabetes. In addition, there was a tendency to an increase in the level of high-density lipoproteins in this group of patients. In general, it can be noted that there was a significant improvement in lipid profile in patients with diabetes: the level of total cholesterol decreased by 28 %, LDL cholesterol — by 34 %, triglycerides — by 24 %. Administration of rosuvastatin did not impair glucose control in any way in the group of patients with DM; moreover, even in the group of people without DM, there was no negative effect of rosuvastatin on fasting glucose level. Conclusions. In general, we can recommend Ozalex in a dose of 10 to 20 mg as an optimal start of statin therapy at the stage of primary care for patients with DM.

References

Nelson A.J., Rochelau S.K., Nicholls S.J. Managing Dyslipidemia in Type 2 Diabetes. Endocrinol. Metab. Clin. 2018 Mar. 47(1). 153-173.

Park Z.H., Juska А., Dyakov D., Patel R.V. Statin-associated incident diabetes: a literature review. Consult Pharm. 2014. 29(5). 317-34.

Simsek S., Schalkwijk C.G., Wolffenbuttel B.Н.R. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes — the CORALL study. Diabet Med. 2012 May. 29(5). 628-31.

Ridker P.М., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11. 380(9841). 565-71.

Mach F., Baigent C., Catapano A.L et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020. 41(1). 111-188.

Published

2021-06-09

Issue

Section

Clinical Researches